• About Us
  • Board of Advisors
  • Contact

MALARIA.com

A Malaria Information and Community Portal

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
Home / Archives for Pyramax

New Treatment for Malaria

May 19, 2012 By Malaria Q&A Leave a Comment

QUESTION New treatment for malaria? ANSWER The most recently developed type of treatment for malaria actually has very ancient origins. The herb wormwood (Artemisia annua) has been used in ancient Chinese medicine for hundreds, even thousands, of years to cure certain fevers. In the 1970s, a Chinese research program intensively sought new medications against malaria, as part of their … [Read more...]

Filed Under: Malaria Q&A Tagged With: ACTs, Artemisia annua, Artemisinin, Chinese medicine, Chloroquine, Coartem, Duo-Cotecxin, lumefantrine, piperaquine, Pyramax, Pyronaridine, resistance, treatment research, wormwood

Malaria Treatments

April 22, 2012 By Malaria Q&A Leave a Comment

QUESTION What are the of different types of antimalaria drugs? ANSWER Most drugs used in treatment are active against the parasite forms in the blood (the form that causes disease) and include: chloroquine atovaquone-proguanil (Malarone®) artemether-lumefantrine (Coartem®) artesunate-pyronaridine (Pyramax®) dihydroartemisinin-piperaquine (Duo-Cotecxin®) mefloquine … [Read more...]

Filed Under: Malaria Q&A Tagged With: anti-malarial medication, Artesunate, artmether, atovaquone-proguanil, Chloroquine, Chloroquine-Resistant Malaria, clindamycin, Coartem, dihydroartemisinin, Doxycycline, Duo-Cotecxin, G6DP deficiency, Lariam, Malaria Treatment, Malarone, Mefloquine, Primaquine, Pyramax, Quinine, severe malaria

Anacor Pharmaceuticals Enters Development Agreement with Medicines for Malaria Venture (MMV)

March 17, 2011 By Malaria.com 1 Comment

Anacor Pharmaceuticals has entered into a development agreement with Medicines for Malaria Venture (MMV) to develop Anacor’s compound AN3661 for the treatment of malaria. Under the agreement, Anacor and MMV will work together on the development of AN3661 through human proof-of-concept studies. AN3661 was developed as part of a research agreement signed by the two parties in April 2010 to … [Read more...]

Filed Under: Malaria News Tagged With: AN3661, Anacor Pharmaceuticals, David Perry, Eurartesim, Medicines for Malaria Venture (MMV), Pyramax

Stay Informed

WWARN Corner

About WWARN

The WorldWide Antimalarial Resistance Network (WWARN) generates innovative resources and reliable evidence to inform the malaria community on the factors affecting the efficacy of antimalarial medicines. Learn more…

  • Fighting Malaria Requires Protecting the Effectiveness of Antimalarial Medicines
  • Data Sharing at IDDO
  • Evidence to inform equitable dosing in very young and malnourished children

More WWARN Stories...

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
  • About Us
  • Board of Advisors
  • Contact

Copyright © 2023 Malaria.com · Log in